Image: New Zealand DoctorCancer vaccines could transform treatment and prevention – but misinformation about mRNA vaccines threatens their potential
• Moderna and Merck announced on August 19, 2026, that their personalized mRNA vaccine, intismeran autogene, successfully passed a late-stage clinical trial. • The vaccine was used in combination with the immunotherapy drug Keytruda to effectively reduce the recurrence of melanoma, a form of skin cancer. • This milestone represents a significant breakthrough in oncology, demonstrating the potential for mRNA technology to transform both cancer treatment and prevention.
nzdoctor.co.nz


![Request for Information - Potential [Placeholder for Prize] - NASA Science](/_next/image?url=https%3A%2F%2Fassets.science.nasa.gov%2Fcontent%2Fdam%2Fscience%2Fmissions%2Fa-step%2FFFR_Earth_Background_20251120%2520.png%2Fjcr%3Acontent%2Frenditions%2Fcq5dam.web.1280.1280.png&w=1920&q=85)

